Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Alvotech - Ordinary Shares (NQ:ALVO)

5.030 -2.620 (-34.25%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Alvotech - Ordinary Shares

< Previous 1 2 3 4 5 6 7 8 9 Next >
Alvotech Reports Financial Results for Full Year 2022 and Provides Business Update
From Alvotech
Via GlobeNewswire
Earnings Scheduled For March 1, 2023
Companies Reporting Before The Bell • Globalstar (AMEX:GSAT) is expected to report quarterly loss at $0.01 per share on revenue of $38.75 million. 
Via Benzinga
uniQure Stock Trying To Close In On Key Technical Measure
uniQure stock had its Relative Strength Rating upgraded to 79 Tuesday -- a nice improvement, but still shy of the 80-plus desired score. 
Via Investor's Business Daily
Alvotech Announces Webcast of 2022 Full Year Financial Results at 8:00 am ET on March 2, 2023
From Alvotech
Via GlobeNewswire
Settlement of Alvotech Private Share Placement Completed
From Alvotech
Via GlobeNewswire
Why Shares of Alvotech Jumped This Week
The Icelandic biotech company has a deal to expand the reach of its Humira biosimilar in Eastern Europe. 
Via The Motley Fool
EMA Confirms Acceptance of Application for AVT04, a Proposed Biosimilar to Stelara® (ustekinumab)
From Alvotech
Via GlobeNewswire
Alvotech Enters Into Commercialization Agreement With Advanz Pharma for Proposed Biosimilar to Xolair® (Omalizumab)
From Alvotech
Via GlobeNewswire
Alvotech and Bioventure Announce Approval of AVT02 (adalimumab) as Simlandi in Saudi Arabia
From Alvotech
Via GlobeNewswire
Alvotech Completes $137 Million Private Share Placement
From Alvotech
Via GlobeNewswire
Alvotech and Fuji Pharma Expand Partnership Adding a New Biosimilar Candidate
From Alvotech
Via GlobeNewswire
Alvotech Initiates Pharmacokinetic Study for AVT05, a Proposed Biosimilar for Simponi® and Simponi Aria®
From Alvotech
Via GlobeNewswire
Alvotech and Teva Announce Acceptance of U.S. Biologics License Application for AVT04, a Proposed Biosimilar to Stelara® (ustekinumab)
From Teva Pharmaceutical Industries Limited
Via Business Wire
Alvotech and Teva Announce Acceptance of U.S. Biologics License Application for AVT04, a Proposed Biosimilar to Stelara® (ustekinumab)
From Alvotech
Via GlobeNewswire
12 Health Care Stocks Moving In Thursday's Intraday Session
 
Via Benzinga
Why AMC Entertainment Shares Are Trading Lower By Around 13%? Here Are 59 Stocks Moving In Thursday's Mid-Day Session
Gainers Core Scientific, Inc. (NASDAQ: CORZ) shares jumped 188% to $0.1471. Core Scientific shares dipped 75% on Wednesday after the company filed for Chapter 11 bankruptcy. 
Via Benzinga
MillerKnoll, Cleveland-Cliffs And Some Other Big Stocks Moving Higher On Thursday
U.S. stocks traded lower, with the Dow Jones dropping over 400 points on Thursday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
 
Via Benzinga
Update on U.S. Regulatory Status of AVT02, Alvotech’s Proposed High-Concentration, Interchangeable Biosimilar to Humira®
From Alvotech
Via GlobeNewswire
Correction to Total Amount in Announcement About Private Placement Published 2022-12-16 09:00 GMT to headline field
From Alvotech
Via GlobeNewswire
Alvotech Completes $59.7 Million Private Placement
From Alvotech
Via GlobeNewswire
Alvotech Shares Start Trading on Nasdaq Iceland Main Market
From Alvotech
Via GlobeNewswire
Why Prometheus Biosciences Shares Are Trading Higher By Over 184%? Here Are 55 Stocks Moving In Wednesday's Mid-Day Session
Gainers Prometheus Biosciences, Inc. (NASDAQ: RXDX) shares jumped 184.2% to $102.49 after the company announced results for PRA023 in both ARTEMIS-UC Phase 2 and APOLLO-CD Phase 2a studies. ARTEMIS-UC... 
Via Benzinga
Alvotech and STADA Broaden Access to Hukyndra® adalimumab biosimilar in Europe
From Alvotech
Via GlobeNewswire
Alvotech Announces Changes to its Leadership Team
From Alvotech
Via GlobeNewswire
Alvotech Secures Financing Facilities of Approximately $136 Million
From Alvotech
Via GlobeNewswire
Alvotech Reports Financial Results for First Nine Months of 2022 And Provides Business Update
From Alvotech
Via GlobeNewswire
Earnings Scheduled For November 15, 2022
Companies Reporting Before The Bell • Alkaline Water Co (NASDAQ:WTER) is likely to report quarterly loss at $0.05 per share on revenue of $18.31 million. 
Via Benzinga
Alvotech Announces Australian Marketing Authorization for AVT02, a Biosimilar to Humira®
From Alvotech
Via GlobeNewswire
Alvotech to Present Switching Study Data for AVT02, a Proposed Biosimilar to Humira®, at 2022 American College of Rheumatology Conference
From Alvotech
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.